share_log

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target

Benzinga ·  Apr 25 07:25

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment